Disease Diagnosis TRIZ Cases

Assessing arginine to modulator ratios enables precise biochemical detection of metabolic states.

Segmented testing for anti-C5a-receptor antibodies resolves diagnostic accuracy versus time loss by prioritizing specific markers before broader screening.

A urine biomarker panel detects lung cancer using specific polyamine metabolites measured via mass spectrometry.

A salivary biomarker predictive score calculates clinical risk using Interleukin-6 and neutrophil concentrations.

A multi-stage microfluidic device uses inertial focusing and ferrohydrodynamic forces to separate cells by size without labeling.

Segmenting lipid profiles into individual species improves CVD risk prediction accuracy by identifying biomarkers linked to plaque rupture.

Particles form biomolecule coronas from biofluids to identify disease markers, resolving the trade-off between diagnostic accuracy and invasive tissue analysis.

A multidimensional biomarker panel detects chronic mental stress through combined immune and hormone analysis.

Functionalized beads capture microparticles for flow cytometry detection, reducing false readings from genetic mutations.

A 99mTc-labeled alpha-hydroxy acid composition detects hydrogen sulfide by forming an insoluble precipitate.

Fluorescently labeled antibodies detect surface antigens on leukemia cells to identify deltanoid-resistant populations via flow cytometry.

A lectin assay detects specific sugar-chain structures to predict reduced renal function in diabetic nephropathy patients.

Measuring protein levels of specific biomarkers in tumor samples predicts therapeutic efficacy, eliminating trial-and-error treatment selection.

Comparing intraocular pressure against intracranial pressure resolves normotension detection limits by accounting for protective pressure gradients.

IgE antibody detection against specific cow milk protein peptides predicts reaction frequency and treatment duration to improve safety.

Atomic force microscopy measures tissue stiffness distributions to classify breast cancer molecular subtypes with high precision.

Replacing invasive biopsies with ELISA-based detection of tissue-specific transcription factor-nucleosome adducts identifies primary tumor origins.

CSF inflammasome protein levels predict functional recovery and guide therapeutic strategies where traditional clinical assessments lack predictive accuracy.

A biosensor detects glycated albumin using ligand binding and impedance changes.

Biomarker panels detect sepsis conditions and assign risk for progression, resolving the contradiction between ruling out sepsis and confirming diagnosis.

Oral lysophosphatidylglycerol compositions modulate ion channels to prevent drug-induced cardiac arrhythmias caused by hERG inhibition.